2025 Retina Update, Part 2: Photobiomodulation, OCT and OCTA Reimbursement, and Surgical Advances

02/07/25 • 27 min

Drs. M. Ali Khan and Ajay Kuriyan join host Dr. Jay Sridhar to discuss updates in the retina space, including the FDA approval of photobiomodulation for dry age-related macular degeneration (AMD), OCT and OCTA reimbursement changes, and surgical technology advances.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Previous Episode

2025 Retina Update, Part 1: Injectables in the Medical Retina Space

Drs. Ashkan Abbey and Ehsan Rahimy join host Dr. Jay Sridhar to discuss recent developments in the medical retina and injectable space, including faricimab versus high-dose aflibercept, biosimilars for ranibizumab and aflibercept, off-label bevacaziumb shortages, dry age-related macular degeneration (AMD) therapies, private equity acquisitions, and the new drug pipeline.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Next Episode

Dilute Hypochlorous Acid for the Treatment of Periorbital Necrotizing Fasciitis

Drs. Louise Mawn and Jonathan Siktberg sit down with host Dr. Amanda Redfern to share their work on a groundbreaking paradigm shift in the treatment of periorbital necrotizing fasciitis with dilute hypochlorous acid.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.